Search Results

Article Topics

Your search for Syed Ali Abutalib, MD, and Kenneth C. Anderson, MD matches 2 pages

Showing 1 - 2

Syed Ali Abutalib, MD, and Kenneth C. Anderson, MD / January 25, 2019 / 2018 ASH Annual Meeting & Exposition

Novel Therapeutics for Relapsed or Refractory Multiple Myeloma, Part 2

Here is an update on several different studies focusing on novel treatments for patients with relapsed or refractory multiple myeloma presented at the 2018 American Society of Hematology (ASH) Annual Meeting & Exposition. The featured therapeutics include the oral agent selinexor in...

hematologic malignancies

multiple myeloma

Syed Ali Abutalib, MD, and Kenneth C. Anderson, MD / January 25, 2019 / 2018 ASH Annual Meeting & Exposition

Novel Treatments in Newly Diagnosed Multiple Myeloma, Part 1

Here is an update on several different studies focusing on novel treatments for patients with newly diagnosed multiple myeloma presented at the 2018 American Society of Hematology (ASH) Annual Meeting & Exposition. Featured therapeutics include daratumumab plus lenalidomide and dexamethasone, ...

Search Results

Article Topics

Your search for Syed Ali Abutalib, MD, and Kenneth C. Anderson, MD matches 2 pages

Novel Therapeutics for Relapsed or Refractory Multiple Myeloma, Part 2

Novel Treatments in Newly Diagnosed Multiple Myeloma, Part 1

CMS Proposes Medicare Coverage With Evidence Development for CAR T-Cell Therapy

FDA Pipeline: Priority Reviews in Renal Cell Carcinoma and Head and Neck Cancer

First-Line Pembrolizumab in Advanced Merkel Cell Carcinoma

Gastric Acid Suppressants May Reduce Survival Outcomes in Patients With Sarcoma Treated With Pazopanib

New Approach to Predicting Response to Pertuzumab and Trastuzumab in Breast Cancer

Selected Abstracts From the San Antonio Breast Cancer Symposium

SABCS 2018: Delayed Initiation of Adjuvant Chemotherapy Associated With Worse Outcomes in Patients With Triple-Negative Breast Cancer

FDA Pipeline: Priority Reviews in Renal Cell Carcinoma and Head and Neck Cancer

Novel Treatments of Myelodysplastic Syndromes

SABCS 2018: KATHERINE Trial: Adjuvant Ado-Trastuzumab Emtansine vs Trastuzumab in Early-Stage HER2-Positive Breast Cancer